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Results: 46 patients satisﬁed criteria for AD (34 F and 12 M), 57 for VaD
(29 F and 28 M) and 26 patients had CDND (12 F and 14 M). 55.8% of
subjects had hypertension (14 CDND, SBP 142±17mmHg, DBP 81±7mmHg;
17 AD, SBP 135±21mmHg, DBP 79±7mmHg and 36 VaD, SBP 140±18mmHg,
DBP 81±7mmHg; P = n.s.). HDL-cholesterol levels were signiﬁcantly different
in the three groups (CDND 43.44±11.39mg/dl, AD 51.71±14.31mg/dl, VaD
43.64±14.58mg/dl; P < 0.05), while no differences in total cholesterol, LDL
cholesterol and triglycerides were detected. AD patients showed signiﬁcantly
lower BDNF levels compared to CDND subjects (CDND 363.5±143.4 pg/ml, AD
264.6±147.6 pg/ml, VaD 304.1±121.8 pg/ml; P < 0.02), also after adjustment
for age and sex. DM had signiﬁcantly lower BDNF levels compared to
NDM (DM 271.4±129.8 pg/ml, NDM 313.9±142.3 pg/ml; P = 0.12). Among
NDM subjects, patients with dementia (AD and VaD) had signiﬁcantly
lower BDNF levels compared to CDND patients (CDND 398.7±148.2 pg/ml,
AD 290.5±138.5 pg/ml; P < 0.03, VaD 297.8±132.4 pg/ml; P < 0.03). Among
DM patients, those patients with AD showed signiﬁcantly lower BDNF
levels compared to VaD and CDND subjects (CDND 293.3±109.6 pg/ml, AD
176.8±150.7 pg/ml, VaD 316.7±98.9 pg/ml; P < 0.02).
Conclusions: Reduced circulating levels of BDNF in diabetic patients and
in subjects with primary dementia could suggest that reduced levels of
neurotrophin could link T2D to cognitive disorders, potentially explaining the
clustering of these conditions in epidemiological studies.
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Diabetes mellitus is a major risk factor for cardiovascular (CV) events.
Many algorithms have been devised to assess CV risk, some of which
speciﬁc for diabetics. Most of them, however, can hardly be extrapolated
to Mediterranean countries.
Aim of this study was to analyze CV risk and the incidence of CV events in a
local cohort of patients with type 2 diabetes.
Methods: Clinical charts of the Diabetes Clinics of Modena in the period
1991 1995 were analyzed. Patients aged 35 65 with type 2 diabetes and no
previous CV disease were eligible. Global CV risk was computed according to
Framingham, RISCARD, Progetto Cuore and UKPDS algorithms and compared
with the actual rate of CV events over the following 10 years.
Results: 2416 patients were screened; 1532 of them (63.4%) were eligible
on the basis of predeﬁned criteria and completeness of data. In such
population an absolute 10-yr risk rate of 14.6% was observed. When looking
at the characteristics of the patients who developed a cardiovascular event
compared to those who did not, we found a signiﬁcant difference in the
prevalence of risk factors as systolic blood pressure, age at visit, smoke,
duration of diabetic disease and HbA1c. COPD and chronic heart failure also
display a higher prevalence in patients with events, suggesting a possible role
of these chronic conditions in developing cardiovascular disease. Interestingly,
most of the subjects presenting with a CV event had a low to moderate risk
estimate at the beginning; this was particularly evident with the Progetto
Cuore algorithm.
Conclusions: Estimation of CV risk is largely dependent on the algorithm
adopted and on the baseline risk of the reference cohort. Equations designed
for a speciﬁc population should be adopted. The overall performance of
presently available functions is however low. Inclusion of additional risk
parameters might hopefully increase the performance of such algorithms,
which is presently clearly unsatisfactory. The algorithm derived from the
present study will be utilized for a prospective evaluation of CV risk in our
local cohort.
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Lipoprotein glomerulopathy (LPG) is a rare disease characterized by laminated
lipid thrombi in the lumina of dilated glomerular capillaries. Apolipoproteins
E and B can be demonstrated in these lipid deposits. The plasma lipid proﬁle
of LPG patients is similar to that of dysbetalipoproteinemia with elevated IDL
and ApoE. Patients often present nephrotic proteinuria but their lipid proﬁle
differs from that of nephrotic syndrome secondary to other kidney diseases.
LPG has been mainly reported in Japanese and Chinese subjects, associated
with novel mutations in APOE gene encoding ApoE.
We have identiﬁed LPG in an Italian woman who at the age of 47 was found to
have a combined hyperlipidemia (TC 376 and TG 306mg/dl) and subsequently
developed proteinuria in the nephrotic range. Renal biopsy demonstrated
lipoprotein thrombi in glomerular capillaries suggesting LPG. The sequence
of APOE gene showed that the patient was: (i) homozygous for epsilon-2
allele [Cys112 and Cys158 in the mature protein] and (ii) heterozygous for
a novel mutation in exon 4: c.502 C>T [Arg 150>Cys in the mature protein].
Since the mutant ApoE has a new cysteine residue it is likely that it forms a
disulﬁde bridge with the other Cys residues of the E2 isoforms, resulting in
ApoE polymerization (dominant negative effect). This is probably the cause
of both dyslipidemia and lipid thrombi in the glomerular capillaries.
In view of the poor response of plasma lipids and renal histology and function
to statin treatment, the patient started lipid-apheresis with reduction of both
dyslipidemia and proteinuria.
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Aim: The maintenance of stable bone mass during adult life is dependent from
the activity of bone resident osteogenic cells, the osteoblasts (OBs), which
are able to mineralize in vitro and form bone in vivo. Impaired osteoblast
recruitment and function have been observed in subjects with osteoporosis,
which have also stiffer arteries than non osteoporotic subjects. Osteoblast
lineage cells with stem cell properties express alkaline-phosphatase and CD34
surface antigens; they have been recently identiﬁed in the peripheral blood
of normal subjects, thus circulating in direct contact with the inner arterial
surface. Whether circulating OBs may contribute to arterial stiffening in
osteoporotic post-menopausal women is unknown.
Methods: The number of circulating OBs was quantiﬁed in peripheral blood
by FACS analysis in 50 post-menopausal osteoporotic women and 35 age-
and sex-matched non-osteoporotic controls. OBs were deﬁned as double
positive alkaline-phosphatase and CD34 cells. All participants underwent
cardiovascular risk assessment, measurement of femoral neck and total hip
bone mineral density (BMD) by Dual-Energy X-ray Absorbptiometry, aortic
pulse wave velocity (aPWV) as an indirect index of arterial stiffness, and
plasma PTH levels.
Results: Levels of circulating double positive alkaline-phosphatase and CD34
OBs and aPWV were higher in osteoporotic post-menopausal women than
in non-osteoporotic controls (2.72±0.77 n/microL vs 0.72±0.12 n/microL,
p = 0.04; 10.4±0.45m/s vs 9.1±0.32m/s, p = 0.03), whereas PTH levels were
comparable in the two groups. In the whole cohort, the number of circulating
OBs was positively correlated with aPWV (rho=0.35, p = 0.002) and negatively
with femoral neck BMD (r = 0.27, p = 0.01) and total hip BMD (r = 0.30,
p = 0.007). Femoral neck BMD and total hip BMD were inversely correlated
with aPWV (r = 0.34, p = 0.003 and r = 0.32, p = 0.005, respectively), whereas
aPWV and PTH levels were positively correlated (rho=0.31, p = 0.007). Linear
regression analysis showed that an increased number of double positive
alkaline-phosphatase and CD34 OBs, age and systolic blood pressure were
all signiﬁcant independent predictor of aPWV (Model R = 0.56, p < 0.001),
independent of PTH levels.
Conclusions: In women with post-menopausal osteoporosis an increased
availability of circulating osteoblasts may reﬂect the possible inﬂuence
of bone-marrow stem cells to bone formation. However, the presence of
increased levels of immature osteoblasts in the blood stream may have a
detrimental impact on arterial compliance, possibly as a consequence of
circulating osteoblast contribution to arterial wall calciﬁcation.
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FH is mainly due to mutations in LDLR gene. Diagnosis is based on evaluation
of family history, patient’s clinical history, physical examination and high level
of LDL-C. We collected 100 new probands with probable diagnosis of FH that
were screened by DHPLC for mutations causing FDB and by “Surveyor method”
or direct sequencing for mutations in LDLR gene. In absence of minute or point
mutations in LDLR gene, we used MLPA to detect major rearrangements.
We identiﬁed the following LDLR novel mutations never described before:
A>C 215 from ATG; c.130 131 ins GT>Fs21 >162aa>X185; c.185 186 ins
T>Fs41>66aa>X108; c.296 297 del CA>S78X; c.382 G>T, C100F; c.366 367
ins C>Fs102>X108; c.391 G>C, D110H; c.431 434 dupl CGGT>Fs125>X159;
c.616 617 ins. A>Fs185>X196; c.648 ins T, D196X; c.676 684 dupl, dupl S205,
D206, E207; IVS4 c.694 +3 ins T; c.968 del G>Fs301>X347; c.1130 G>C, C356S;
IVS8 c.1187 1 G>A; c.1211 C>T, T383I; c.1230 G>C, R389S; c.1296 1298 del
GGA, del D412; c.1570 G>A, V503M; c.1586 G>A, G508D; c.1644 T>A, N527L;
c.1721 G>A, R553H; c.1859 G>A, W599X; c.1978 C>A, Q639L; c.2171 C>T,
T703I; c.2225 del C>Fs721>X743; IVS16 c.2389 +5 G>A; IVS16 c.2390 1 G>A.
We also identiﬁed for the ﬁrst time in Italy the following mutation previously
described elsewhere: exons 5 6 del; c.58 G>A, G-2>R; IVS1 c.68 1 G>C; c.661
G>T, D200Y; c.681 C>G, D206E; c.953 G>A, C297T; c.977 C>G, S305C; c.1048
C>T, R329X; c.1104 C>A, C347X; c.1246 C>T, R395W; c.1257 C>G, Y398X;
c.1285 G>A, V408M; c.1474 G>A, D471N; c.1618 G>A, A519T; c.1879 G>A,
A606T; IVS13 c.1988 2 A>G; c.2132 G>A, C690T; c.2389 G>A, V776M.
